A hereditary cancer syndrome (familial/family cancer syndrome, inherited cancer syndrome, cancer predisposition syndrome, cancer syndrome, etc.) is a genetic disorder in which inherited genetic mutations in one or more genes predispose the affected individuals to the development of cancer and may also cause early onset of these cancers. Hereditary cancer syndromes often show not only a high lifetime risk of developing cancer, but also the development of multiple independent primary tumors.
Many of these syndromes are caused by mutations in tumor suppressor genes, genes that are involved in protecting the cell from turning cancerous. Other genes that may be affected are DNA repair genes, oncogenes and genes involved in the production of blood vessels (angiogenesis). Common examples of inherited cancer syndromes are hereditary breast-ovarian cancer syndrome and hereditary non-polyposis colon cancer (Lynch syndrome).
Hereditary cancer syndromes underlie 5 to 10% of all cancers and there are over 50 identifiable hereditary forms of cancer. Scientific understanding of cancer susceptibility syndromes is actively expanding: additional syndromes are being found, the underlying biology is becoming clearer, and genetic testing is improving detection, treatment, and prevention of cancer syndromes. Given the prevalence of breast and colon cancer, the most widely recognized syndromes include hereditary breast-ovarian cancer syndrome and hereditary non-polyposis colon cancer (Lynch syndrome).
Some rare cancers are strongly associated with hereditary cancer predisposition syndromes. Genetic testing should be considered with adrenocortical carcinoma; carcinoid tumors; diffuse gastric cancer; fallopian tube/primary peritoneal cancer; leiomyosarcoma; medullary thyroid cancer; paraganglioma/pheochromocytoma; renal cell carcinoma of chromophobe, hybrid oncocytic, or oncocytoma histology; sebaceous carcinoma; and sex cord tumors with annular tubules. Primary care physicians can identify people who are at risk of a hereditary cancer syndrome.
Cette page est générée automatiquement et peut contenir des informations qui ne sont pas correctes, complètes, à jour ou pertinentes par rapport à votre recherche. Il en va de même pour toutes les autres pages de ce site. Veillez à vérifier les informations auprès des sources officielles de l'EPFL.
The course covers in detail molecular mechanisms of cancer development with emphasis on cell cycle control, genome stability, oncogenes and tumor suppressor genes.
This course provides a comprehensive overview of the biology of cancer, illustrating the mechanisms that cancer cells use to grow and disseminate at the expense of normal tissues and organs.
Immunoengineering is an emerging field where engineering principles are grounded in immunology. This course provides students a broad overview of how engineering approaches can be utilized to study im
Le ou est une susceptibilité augmentée de développer un cancer du côlon et un cancer de l'endomètre, de l'ovaire, de l'estomac, de l'intestin grêle, du foie, de l'appareil urinaire supérieur, du cerveau et de la peau. Les personnes porteuses de ce syndrome ont un risque de 10% avant 50 ans et 40% avant 70 ans de développer un cancer du côlon dont les deux tiers surviennent sur le colon droit avec un âge moyen de diagnostic de 44 ans.
Prophylactic surgery (also known as preventive surgery or risk-reducing surgery), is a form of surgery whose purpose is to minimize or prevent the risk of developing cancer in an organ or gland that has yet to develop cancer and is known to be at high risk of developing cancer. This form of preventive healthcare may include surgeries such as mastectomies, oophorectomies, colectomies and surgical corrections, such as the surgical correction of cryptorchidism or undescended testis.
La sclérose tubéreuse de Bourneville (ou STB) est une maladie autosomique dominante faisant partie des phacomatoses. Elle se manifeste par le développement de tumeurs bénignes dans de nombreux organes (c'est pour cela qu'elle est dite « multisystémique »). Elle comporte des manifestations cutanées, cardiaques, cérébrales et rénales. La pénétrance est incomplète, le phénotype à la naissance est donc difficilement prévisible. Cette maladie est d'abord décrite par Désiré-Magloire Bourneville en 1880 bien que les manifestations dermatologiques furent décrites en 1835 par Pierre Rayer.
Explore l'immunothérapie contre le cancer, les rôles du système immunitaire dans le cancer, les progrès récents et les concepts d'administration de médicaments à l'aide de nanoparticules et de polymères.
Couvre les caractéristiques du cancer, des oncogènes, des gènes suppresseurs de tumeurs, des métastases et des altérations génétiques à l'origine de la tumorigénèse.
Couvre les caractéristiques du cancer, des oncogènes, de la réparation de l'ADN, des télomères, des virus, du cycle cellulaire, des cellules souches, des métastases et de l'instabilité génétique.
Dendritic cells (DCs) are specialized myeloid cells with the ability to uptake, process, andpresent antigens to T lymphocytes. They also generate cytokine and chemokine gradients thatregulate immune cell trafficking, activation, and function. Monocyte-deri ...
EPFL2024
, , , , , , , , ,
Heterochromatin loss and genetic instability enhance cancer progression by favoring clonal diversity, yet uncontrolled replicative stress leads to mitotic catastrophe and inflammatory responses that promote immune rejection. KRAB domain-containing zinc fin ...
2024
, , , ,
Metabolic changes precede malignant histology. However, it remains unclear whether detectable characteristic metabolome exists in esophageal squamous cell carcinoma (ESCC) tissues and biofluids for early diagnosis. Here, we conduct NMR- and MS-based metabo ...